Norway's Clavis inks cancer drug pact with Translational Therapeutics; Indian regulators standardize adverse event reporting;

 @FierceBiotech: Shire: A takeover target? Report | Follow @FierceBiotech

 @JohnCFierce: In case you missed in, the FDA approved boceprevir on Fri. Look for a telaprevir approval notice soon. | Follow @JohnCFierce

> Norway's Clavis has inked a development deal with Translational Therapeutics, getting undisclosed milestones and a minority equity stake for one of its cancer drug programs. Clavis release

> Regulators in India are seeking a uniform reporting process for adverse events which occur in the growing number of clinical trials in the subcontinent. The move follows news reports that developers frequently don't compensate the families of patients who have died during trials. Report

> Biogen Idec reports that Australian regulators approved the MS drug Fampyra. Acorda, which developed the treatment, markets the drug as Ampyra. Story

> Isis earned a $3 million payment from GlaxoSmithKline as it launched a sixth program under its collaboration to discover and develop drugs to treat rare and infectious diseases. Isis release

Pharma News

@FiercePharma: Google near $500M settlement in pharmacy probe. Article | Follow @FiercePharma

> Whose hep C blockbuster will be biggest? Piece

> Big Pharma's impending showdown in specialty markets. Report

> Shanghai Pharma IPO yields $2B. Article

> Takeda moves forward on China growth strategy. Story

> EMA board vote leaves agency leaderless. Item

> Teva snaps up 57% of Japan's Taiyo for $460M. News

FierceBiotech IT

> PerkinElmer acquires Labtronics, buyouts pile up. Item

> Scientists mount computer-aided attack on H1N1 flu virus. Report

> Sequencing DNA is cheap, analysis not so much. News

> "VAAST" software could spot disease genes. Piece

> My visit to Nimbus, Bill Gates' bet on virtual drug discovery. Editorial

> Report: SAS hatches new "think tank" for life sciences, healthcare analytics. Story

Medical Device News

> Neuronetics completes Series E, raises $30M. Article

> Stryker to buy Orthovita for $304M. Item

> Report: EU needs to do more to ensure device safety. Story

> Harmac to create 100 jobs in Ireland. Report

> Sorensen named head of Siemens Healthcare in U.S., Canada. News

And Finally... Psychologist Simon Baron-Cohen considers whether a brain scan, genotyping and a case history could help diagnose cruelty. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.